Multigene testing replacing BRCA tests for breast cancer risk, Stanford researcher says

May 10, 2018

The use of genetic tests aimed at detecting the presence of mutations in the BRCA1 and BRCA2 genes in women with breast cancer is rapidly declining in favor of tests that can detect multiple cancer-associated mutations, according to researchers at the Stanford University School of Medicine and five other U.S. medical centers.

Some researchers had wondered whether multigene testing, which may identify genetic mutations of uncertain clinical significance, would lead more women to consider prophylactic mastectomies -- a surgery in which both breasts are removed to prevent future cancers -- out of an abundance of caution. However, the current study did not show an increase in mastectomies associated with testing more genes.

The shift reflects a growing acknowledgement by clinicians that multigene panel tests can yield more clinically useful information for patients and their unaffected relatives, the researchers said.

Overall, multigene panels were about twice as likely as the tests for BRCA1 and BRCA2 to identify disease-associated genetic variants, the study found. However, multigene testing was more likely than the BRCA-only testing to be delayed until after surgery to remove the tumor. This time lag may limit a patient's treatment options, the researchers said.

'Becoming the norm'

"In general, multigene panel tests yield more clinically useful results and are rapidly becoming the norm," said Allison Kurian, MD, associate professor of medicine and of health research and policy at Stanford. "Newly diagnosed women should ask their doctors whether they may be appropriate candidates for genetic testing. They should also advocate for the opportunity to discuss genetic testing and its implications with an experienced clinician, such as a genetic counselor, in a timely manner."

A paper describing the research will be published May 10 in JAMA Oncology. Kurian is the lead author. Steven Katz, MD, MPH, professor of medicine and of health management and policy at the University of Michigan, is the senior author.

Multigene panel tests are more likely than BRCA-only tests to yield information about both a patient and her family members, who may be unwitting carriers of disease-associated mutations. "This is very important because it offers the opportunity for genetically targeted, primary cancer prevention in unaffected relatives," Kurian said. "Some prior research has shown that this 'cascade testing' of unaffected relatives is cost-effective, and there are currently several initiatives underway to improve upon the delivery and success rates of cascade testing."

The researchers surveyed over 5,000 women who had been diagnosed with stage-0 to stage-2 breast cancer between 2013 and 2015. They asked the women if they'd had genetic testing, and, if so, who ordered it, when it was performed and what type of tests they underwent. A novel feature of this study was that genetic results came directly from the testing laboratories and were linked to population-based cancer registry data. This data linkage provided substantially greater depth and accuracy of genetic information than in previous studies.

They found that only about one-quarter of the women had received any genetic testing. This number stayed relatively constant throughout the two-year period. However, of those who were tested, the proportion who received multigene panel testing increased steadily over time, from about 26 percent of those tested in early 2013 to about 66 percent in mid-2015. Conversely, the proportion of women who received BRCA-only testing during the same time period decreased from about 74 percent to about 34 percent.

Multigene panel testing was about twice as likely as BRCA-only testing to identify disease-associated mutations. But it was also more likely to reveal mutations of uncertain clinical significance, particularly in racial or ethnic minorities. This disparity is likely due to the fact that most genes were sequenced first in white patients, and the causative effect of variations in other minorities is not clear. This finding emphasizes the need for research in diverse populations to clarify genetic uncertainty and reduce racial disparities in the clarity of genetic test results, the researchers say.

Timing of tests varied

The timing of the tests also varied, the study found. Although the majority of the women tested got their results prior to surgery to remove the tumor, many did not. About 33 percent of women receiving multigene panel testing were tested after surgery, versus about 20 percent of women receiving BRCA-only testing -- perhaps due to a recognition by clinicians that interpreting the results of a multigene panel can be complex and requires the expertise of genetic counselors, who are not always rapidly available.

"Furthermore, patients and their clinicians may view genetic testing as a lower priority than tumor biology and pathology testing which most directly inform the treatment options," said Katz.

"As genetic testing has become more comprehensive and less expensive, we have begun to see a significant problem in terms of the genetic-counselor workforce," Kurian said. "More genetic counselors are needed, and they should be integrated into routine cancer care. There is also a need for new care-delivery models that effectively triage appropriate patients to timely genetic counseling."
-end-
Researchers from the University of Southern California, Emory University and the Memorial Sloan-Kettering Cancer Center also contributed to the study.

The research was supported by the National Institutes of Health (grant P01CA163233), the National Cancer Institute and the University of Michigan Cancer Center.

Stanford's departments of Medicine and of Health Research and Policy also supported the work.

The Stanford University School of Medicine consistently ranks among the nation's top medical schools, integrating research, medical education, patient care and community service. For more news about the school, please visit http://med.stanford.edu/school.html. The medical school is part of Stanford Medicine, which includes Stanford Health Care and Stanford Children's Health. For information about all three, please visit http://med.stanford.edu.

Stanford Medicine

Related Breast Cancer Articles from Brightsurf:

Oncotarget: IGF2 expression in breast cancer tumors and in breast cancer cells
The Oncotarget authors propose that methylation of DVDMR represents a novel epigenetic biomarker that determines the levels of IGF2 protein expression in breast cancer.

Breast cancer: AI predicts which pre-malignant breast lesions will progress to advanced cancer
New research at Case Western Reserve University in Cleveland, Ohio, could help better determine which patients diagnosed with the pre-malignant breast cancer commonly as stage 0 are likely to progress to invasive breast cancer and therefore might benefit from additional therapy over and above surgery alone.

Partial breast irradiation effective treatment option for low-risk breast cancer
Partial breast irradiation produces similar long-term survival rates and risk for recurrence compared with whole breast irradiation for many women with low-risk, early stage breast cancer, according to new clinical data from a national clinical trial involving researchers from The Ohio State University Comprehensive Cancer Center - Arthur G.

Breast screening linked to 60 per cent lower risk of breast cancer death in first 10 years
Women who take part in breast screening have a significantly greater benefit from treatments than those who are not screened, according to a study of more than 50,000 women.

More clues revealed in link between normal breast changes and invasive breast cancer
A research team, led by investigators from Georgetown Lombardi Comprehensive Cancer Center, details how a natural and dramatic process -- changes in mammary glands to accommodate breastfeeding -- uses a molecular process believed to contribute to survival of pre-malignant breast cells.

Breast tissue tumor suppressor PTEN: A potential Achilles heel for breast cancer cells
A highly collaborative team of researchers at the Medical University of South Carolina and Ohio State University report in Nature Communications that they have identified a novel pathway for connective tissue PTEN in breast cancer cell response to radiotherapy.

Computers equal radiologists in assessing breast density and associated breast cancer risk
Automated breast-density evaluation was just as accurate in predicting women's risk of breast cancer, found and not found by mammography, as subjective evaluation done by radiologists, in a study led by researchers at UC San Francisco and Mayo Clinic.

Blood test can effectively rule out breast cancer, regardless of breast density
A new study published in PLOS ONE demonstrates that Videssa® Breast, a multi-protein biomarker blood test for breast cancer, is unaffected by breast density and can reliably rule out breast cancer in women with both dense and non-dense breast tissue.

Study shows influence of surgeons on likelihood of removal of healthy breast after breast cancer dia
Attending surgeons can have a strong influence on whether a patient undergoes contralateral prophylactic mastectomy after a diagnosis of breast cancer, according to a study published by JAMA Surgery.

Young breast cancer patients undergoing breast conserving surgery see improved prognosis
A new analysis indicates that breast cancer prognoses have improved over time in young women treated with breast conserving surgery.

Read More: Breast Cancer News and Breast Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.